ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Multicentre clinical trial experience with the HeartMate 3 left ventricular assist device: 30-day outcomes

Wednesday, September 7, 2016

Submitted by

Source

Source Name: Eur J Cardiothorac Surg

Author(s)

Daniel Zimpfer, Ivan Netuka, Jan D. Schmitto, Yuriy Pya, Jens Garbade, Michiel Morshuis, Friedhelm Beyersdorf, Silvana Marasco, Vivek Rao, Laura Damme, Poornima Sood, and Thomas Krabatsch

The international multicenter CE Mark clinical trial of the HeartMate 3 Left Ventricular Assist System included 50 patients. Thirty-day survival was 98%, bleeding and strokes were observed in 30% and 4%, respectively.

Add comment

Log in or register to post comments